Digestive System Diseases

At Synexus Polska the focus is on improving outcomes for patients with erosive esophagitis caused by gastroesophageal reflux disease, evaluating newer acid‑suppression agents to sustain healing after initial treatment.

  • Healing of erosive esophagitis
  • Maintenance therapy comparison
  • Long‑term safety monitoring
  • Patient‑reported symptom relief

The trials aim to confirm that the investigational drug can maintain mucosal healing more effectively than standard therapy, offering patients a reliable option for long‑term disease control.

Immune System Diseases

Research at the Katowice site includes studies on moderate‑to‑severe plaque psoriasis, where novel immune‑modulating agents are compared for cardiovascular safety and overall efficacy.

  • Long‑term safety of targeted therapies
  • Cardiovascular outcome assessment
  • Comparative effectiveness of biologics
  • Impact on quality of life

These investigations seek to ensure that emerging treatments not only clear skin lesions but also do not increase heart‑related risks for patients.

Nutritional and Metabolic Diseases

The centre conducts trials on non‑alcoholic steatohepatitis and its broader category metabolic dysfunction‑associated steatohepatitis, as well as on obesity, to test therapies that may halt liver fibrosis and improve metabolic health.

  • Fibrosis regression in compensated cirrhosis
  • Event‑free survival metrics
  • Weight reduction outcomes
  • Liver function improvement

The goal is to determine whether new agents can safely reduce liver damage and support healthier body weight, addressing two major contributors to chronic disease.

Respiratory Tract Diseases

Studies targeting respiratory syncytial virus infections evaluate the immune response generated by a revaccination schedule of the RSVPreF3 OA vaccine in adults over 60 years old.

  • Humoral immunity after revaccination
  • Seasonal timing of dose administration
  • Safety profile in older participants
  • Potential reduction in RSV‑related illness

By measuring antibody levels and monitoring adverse events, the research aims to confirm that the vaccine provides robust protection for the elderly during peak RSV seasons.

Virus Diseases

In addition to respiratory studies, the site explores broader virus diseases strategies, focusing on vaccine effectiveness and immune monitoring to curb viral spread in vulnerable populations.

  • Evaluation of vaccine immunogenicity
  • Development of antiviral prophylaxis
  • Assessment of public health impact
  • Safety surveillance across age groups

The overarching aim is to advance preventive measures that reduce infection rates and improve community health outcomes.